APA

van den Berg V. J., Haskard D. O., Fedorowski A., Hartley A., Kardys I., Caga-Anan M., Akkerhuis K. M., Oemrawsingh R. M., van Geuns R. J., de Jaegere P., van Mieghem N., Regar E., Ligthart J. M. R., Umans V. A. W. M., Serruys P. W., Melander O., Boersma E. & Khamis R. Y. (20190220). IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). : EBioMedicine.

Chicago

van den Berg Victor J, Haskard Dorian O, Fedorowski Artur, Hartley Adam, Kardys Isabella, Caga-Anan Mikhail, Akkerhuis K Martijn, Oemrawsingh Rohit M, van Geuns Robert Jan, de Jaegere Peter, van Mieghem Nicolas, Regar Evelyn, Ligthart Jurgen M R, Umans Victor A W M, Serruys Patrick W, Melander Olle, Boersma Eric and Khamis Ramzi Y. 20190220. IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). : EBioMedicine.

Harvard

van den Berg V. J., Haskard D. O., Fedorowski A., Hartley A., Kardys I., Caga-Anan M., Akkerhuis K. M., Oemrawsingh R. M., van Geuns R. J., de Jaegere P., van Mieghem N., Regar E., Ligthart J. M. R., Umans V. A. W. M., Serruys P. W., Melander O., Boersma E. and Khamis R. Y. (20190220). IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). : EBioMedicine.

MLA

van den Berg Victor J, Haskard Dorian O, Fedorowski Artur, Hartley Adam, Kardys Isabella, Caga-Anan Mikhail, Akkerhuis K Martijn, Oemrawsingh Rohit M, van Geuns Robert Jan, de Jaegere Peter, van Mieghem Nicolas, Regar Evelyn, Ligthart Jurgen M R, Umans Victor A W M, Serruys Patrick W, Melander Olle, Boersma Eric and Khamis Ramzi Y. IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). : EBioMedicine. 20190220.